CD274 and cancer: At least three clinical studies evaluating the efficacy of ICI in this setting have recently been published2, 3, 4; disappointingly showing that the objective response rate for PD1 inhibition (pembrolizumab and nivolumab) and PD‐L1 inhibition (atezolizumab) for pediatric cancer patients is low.